The question that trips up most P2 and P3 students is not which agent lowers A1C the most. It is why an attending started a patient sitting at 7.4 percent on semaglutide rather than adding a sulfonylurea for a fraction of the cost.
If you learned diabetes pharmacotherapy as a ladder, that decision looks arbitrary. It is not. The modern approach asks a different opening question, and once you internalize it, most therapeutics exam vignettes and most rotation discussions resolve quickly.
Stop reading the algorithm as a ladder
The treatment figure in Section 9 of the ADA Standards of Care is not a sequence. It splits into two halves that run in parallel. One side addresses mitigation of diabetes-related complications and end-organ effects. The other side addresses weight and glycemic management goals.
That structure is the whole lesson. A patient with heart failure and an A1C of 7.2 percent may still need an SGLT2 inhibitor, because the indication driving that choice has nothing to do with the A1C. Organ protection is not a reward for failing at glycemic control first.
Metformin remains a reasonable foundation for many patients, but a comorbidity-driven agent does not wait its turn behind it.
Four questions, in this order
1. What else does this patient have?
Screen for atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease before you look at the A1C. If any are present, the class is largely chosen for you, and the glycemic numbers become a secondary consideration rather than the trigger.
2. What are the weight goals?
Weight is not a side benefit in current practice. It is a therapeutic target with its own recommendations, and it legitimately drives class selection.
3. How far is this patient from goal?
Now the efficacy tiers matter. The largest A1C reductions come from treatment plans including insulin, select GLP-1 receptor agonists, and tirzepatide. DPP-4 inhibitors produce the smallest reductions. A patient 3 points from goal and a patient 0.4 points from goal are not the same problem.
4. What will actually work for this person?
Cost, insurance coverage, renal dosing, injection tolerance, hypoglycemia risk, and pill burden. This is the question students skip and preceptors ask first.
What each class is really for
Learn each class by its job, not just its mechanism.
-
Metformin.
Inexpensive, weight neutral, extensive experience. Watch renal thresholds and remember that long-term use is associated with vitamin B12 deficiency, which means periodic B12 testing belongs on your monitoring plan and matters for any patient with neuropathy symptoms.
-
SGLT2 inhibitors.
Heart failure and chronic kidney disease. Modest A1C lowering that attenuates as eGFR falls, while the cardiorenal benefit persists. Genital mycotic infections, volume depletion, and euglycemic DKA are the counseling points.
-
GLP-1 receptor agonists.
Atherosclerotic cardiovascular disease, weight, and substantial A1C reduction. The 2026 Standards also address their role in advanced chronic kidney disease and in metabolic dysfunction-associated steatohepatitis.
-
Dual GIP and GLP-1 receptor agonist.
Tirzepatide now appears in recommendations for symptomatic heart failure with preserved ejection fraction and for patients with MASH, alongside its weight and glycemic role.
-
DPP-4 inhibitors.
Weight neutral, generally well tolerated, oral, and the weakest glycemic performers of the incretin-based options. Never combine with a GLP-1 receptor agonist.
-
Sulfonylureas.
Fast, cheap, effective. Hypoglycemia and weight gain are the trade. Still appropriate in specific circumstances, particularly cost-constrained ones.
-
Thiazolidinediones.
Avoid in heart failure. Pioglitazone retains interest for hepatic steatosis and insulin resistance.
-
Insulin.
Highest glycemic efficacy, and the answer when a patient presents with catabolic features, marked hyperglycemia, or evidence that type 1 diabetes is the real diagnosis.
Three traps worth flagging before your exam
-
Treating declining eGFR as a reason to stop an SGLT2 inhibitor.
The glucose-lowering effect diminishes. The kidney and heart failure benefit does not track with it. Students conflate the two constantly.
-
Stacking incretin-based therapies.
A DPP-4 inhibitor added to a GLP-1 receptor agonist adds cost and risk without meaningful benefit.
-
Choosing by A1C reduction alone.
If your rationale in a written case is only "this lowers A1C by 1.5 percent," you have skipped the reasoning your preceptor is grading.
Build the comparison table you will actually use
The classes are not hard to memorize individually. What takes time is holding them side by side: efficacy, weight effect, renal considerations, cardiovascular and renal outcome data, hypoglycemia risk, and cost, all in one view you can scan during a topic discussion.
Megan Adelman, PharmD, BCPS, built that view as a reference chart for students and practicing clinicians.
Recommended Resource
Created by Megan Adelman, PharmD, BCPS, this reference chart puts every class side by side — efficacy, weight effect, renal considerations, cardiovascular and renal outcomes, hypoglycemia risk, and cost — in one scannable view. Worth having open the week you start ambulatory care, and reviewing the week before your therapeutics exam.
Get the Diabetes Medication Chart
It is the kind of resource worth having open the week you start your ambulatory care rotation, and worth reviewing the week before your therapeutics exam.
Explore more resources from
Megan Adelman, PharmD, BCPS, BCGP
and other verified creators across the
RelayEd community
.
Guideline content reflects the American Diabetes Association Standards of Care in Diabetes 2026, Section 9, Pharmacologic Approaches to Glycemic Treatment. Always confirm recommendations against the current Standards and your institution's protocols. Educational content only. Written by RelayEd.
